Reported Earnings • Jul 02
Full year 2025 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in FY 2024) Full year 2025 results: UK£0.001 loss per share (improved from UK£0.002 loss in FY 2024). Revenue: UK£11.6m (down 2.9% from FY 2024). Net loss: UK£895.0k (loss narrowed 54% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 33 percentage points per year, which is a significant difference in performance. Announcement • Jun 05
Surgical Innovations Group plc, Annual General Meeting, Jun 30, 2026 Surgical Innovations Group plc, Annual General Meeting, Jun 30, 2026. Location: the offices of singer capital markets, 1 bartholomew lane, ec2n 2ax, london United Kingdom Reported Earnings • Apr 21
Full year 2025 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in FY 2024) Full year 2025 results: UK£0.001 loss per share (improved from UK£0.002 loss in FY 2024). Revenue: UK£11.6m (down 2.9% from FY 2024). Net loss: UK£895.0k (loss narrowed 54% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 31 percentage points per year, which is a significant difference in performance. New Risk • Apr 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£4.20m market cap, or US$5.68m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Announcement • Apr 09
Surgical Innovations Group plc to Report Fiscal Year 2025 Final Results on Apr 21, 2026 Surgical Innovations Group plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on Apr 21, 2026 Board Change • Oct 05
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Member of the Clinical Advisory Board Chris Sutton is the most experienced director on the board, commencing their role in 2012. Independent Non-executive Director Keyvan Djamarani was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Announcement • Oct 02
Surgical Innovations Group plc Appoints Andrew Boteler as Non-Executive Director, Chair of the Audit Committee, Chair of the Remuneration Committee and Member of the Nominations Committee, Effective from 29 September 2025 Octopus AIM VCT plc announced that Andrew Boteler, Non-Executive Director and Chair of the Audit Committee of the Company, has been appointed as a Non-Executive Director, Chair of the Audit Committee, Chair of the Remuneration Committee and member of the Nominations Committee of Surgical Innovations Group plc with effect from 29 September 2025. Announcement • Sep 18
Surgical Innovations Group plc to Report First Half, 2025 Results on Sep 29, 2025 Surgical Innovations Group plc announced that they will report first half, 2025 results on Sep 29, 2025 New Risk • Jul 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£409k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£409k free cash flow). Market cap is less than US$10m (UK£6.53m market cap, or US$9.00m). Announcement • Jun 04
Surgical Innovations Group plc, Annual General Meeting, Jun 27, 2025 Surgical Innovations Group plc, Annual General Meeting, Jun 27, 2025. Location: the offices of singer capital markets, 1 bartholomew lane, ec2n 2ax, london United Kingdom Reported Earnings • May 31
Full year 2024 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in FY 2023) Full year 2024 results: UK£0.002 loss per share (further deteriorated from UK£0.001 loss in FY 2023). Revenue: UK£11.9m (flat on FY 2023). Net loss: UK£1.94m (loss widened 282% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance. New Risk • Apr 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£4.66m market cap, or US$6.20m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change). Announcement • Apr 10
Surgical Innovations Group plc Provides Earnings Guidance for the Year Ended 31 December 2024 Surgical Innovations Group plc provided earnings guidance for the year ended 31 December 2024. For the year, the company expects to report revenues of not less than £11.8 million. New Risk • Feb 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£594k free cash flow). Market cap is less than US$10m (UK£6.06m market cap, or US$7.54m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). Announcement • Feb 12
Surgical Innovations Group plc Announces CFO Changes Surgical Innovations Group plc announced the appointment of Brent Greetham as Chief Financial Officer (CFO) with effect from 24 February 2025. Chris Martin, current Group Chief Financial Officer, will be leaving the business to pursue another opportunity, and will step down from the Board on 14 February 2025. Brent brings with him over 25 years' experience in the life sciences sector, having held senior finance leadership roles in various life science, biotech, and manufacturing organisations. His most recent role was with Charles River Laboratories, where he served as the Senior Finance Director for their Discovery division for nearly seven years. Prior to this, from 2011, Brent held finance leadership roles with Thermo Fisher Scientific, Gilead Sciences and Mission Therapeutics. Brent became a Chartered Accountant in 2004, having initially studied at Sheffield Hallam University, obtaining a degree in Accounting and Finance. Brent began his career in 1998 with the Grampian Country Food Group. Previous directorships and partnerships held in the past five years: Argenta Discovery 2009 Limited; Charles River Discovery Research Services UK Limited; Biofocus DPI (Holdings) Ltd. Reported Earnings • Oct 02
First half 2024 earnings released: UK£0.001 loss per share (vs UK£0 in 1H 2023) First half 2024 results: UK£0.001 loss per share (further deteriorated from UK£0 in 1H 2023). Revenue: UK£6.18m (up 9.3% from 1H 2023). Net loss: UK£487.0k (loss widened 30% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. New Risk • Oct 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£594k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£594k free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Market cap is less than US$10m (UK£5.60m market cap, or US$7.46m). Announcement • Sep 10
Surgical Innovations Group plc to Report First Half, 2024 Results on Sep 30, 2024 Surgical Innovations Group plc announced that they will report first half, 2024 results on Sep 30, 2024 Announcement • May 25
Surgical Innovations Group plc, Annual General Meeting, Jun 17, 2024 Surgical Innovations Group plc, Annual General Meeting, Jun 17, 2024. Location: the companys offices, clayton wood house, 6 clayton wood bank, ls16 6qz, leeds United Kingdom New Risk • Apr 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Market cap is less than US$10m (UK£4.66m market cap, or US$5.77m). Reported Earnings • Apr 18
Full year 2023 earnings released Full year 2023 results: Revenue: UK£12.0m (up 5.9% from FY 2022). Net loss: UK£509.0k (down 293% from profit in FY 2022). New Risk • Apr 07
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£4.66m market cap, or US$5.89m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change). New Risk • Feb 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£6.06m market cap, or US$7.61m). Minor Risk Share price has been volatile over the past 3 months (7.4% average weekly change). Announcement • Feb 12
Surgical Innovations Group plc Announces Intention of Paul Hardy to Step Down from Position of Independent Non-Executive Director Surgical Innovations Group Plc announced that Paul Hardy, having entered his ninth year as a Director, has notified the Board of his intention to step down from his position of Independent Non-executive Director (NED) at the Company's AGM which is expected to be held in June this year. Paul chairs the Audit Committee and will retain this position until he steps down. The Board will begin an extensive search for a replacement NED to ensure orderly succession and will provide further updates in due course. Announcement • Dec 05
Surgical Innovations Group plc Announces Board Change Surgical Innovations Group Plc announced that Keyvan Djamarani has been appointed as Independent Non-executive Director with immediate effect. This follows an extensive process led by an independent head-hunter. At the same time Nigel Rogers, who previously served time as Chair of the Company, will step down from the Board. Keyvan has over 30 years' relevant experience, holding numerous leadership roles in product development within manufacturing organizations covering medical and pharmaceutical drug delivery devices. He has a track record of delivering increased sales, profitability and business critical programmes and projects. Most recently he spent over nine years as Managing Director/Business President at Bespak Europe, amedical and pharmaceutical drug delivery devices business. Keyvan began his career at Unilever working in their Detergents and Personal Products Divisions prior to joining Bespak. At Bespak, Keyvan held several roles across their European and North American divisions. Within this period, from 2002 to 2005, Keyvan was General Manager and President of Bespak Inc. and from 2010 to 2013, Keyvan became CEO of King Systems, an airways management business, encompassing design, development and manufacture of airway management products. Keyvan was most recently a Non-executive Director of CEME Ltd, a not-for-profit business enterprise operating on a 19-acre campus, home to over 100 engineering, technology and training businesses - a role he held for over 16 years. As announced on 22 May 2023,Nigel Rogers will step down from the Board with immediate effect,concluding the final part of the planned Board succession process. Nigel joined the Board in 2015, bringing stability to the Company at a critical time. Dr. Keyvan Mehdi Djamarani (aged 62) is currently, or has during the past five years, been a director of the following companies: Previous directorships or partnerships: Centre for Engineering and Manufacturing Excellence Ltd, Bespak Europe Limited, Integrated Aluminium Components Limited, The Medical House Group Limited, The Medical House Limited, The Medical House Products Limited, Medical House (ASI) Limited, Hyperlyser Limited. Reported Earnings • Sep 22
First half 2023 earnings released: EPS: UK£0 (vs UK£0 in 1H 2022) First half 2023 results: EPS: UK£0 (in line with 1H 2022). Revenue: UK£5.65m (up 4.4% from 1H 2022). Net loss: UK£374.0k (loss widened UK£360.0k from 1H 2022). Revenue is expected to decline by 106% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in the United Kingdom are expected to grow by 6.2%. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Sep 07
Surgical Innovations Group plc to Report First Half, 2023 Results on Sep 19, 2023 Surgical Innovations Group plc announced that they will report first half, 2023 results on Sep 19, 2023 Announcement • May 26
Surgical Innovations Group plc, Annual General Meeting, Jun 27, 2023 Surgical Innovations Group plc, Annual General Meeting, Jun 27, 2023, at 10:00 Coordinated Universal Time. Location: Clayton Wood House, 6 Clayton Wood Bank, Leeds Leeds United Kingdom Announcement • May 22
Surgical Innovations Group plc Appoints Jonathan Glenn as Senior Independent Non-Executive Director and Chairman-Designate Surgical Innovations Group Plc announced the appointment of Jonathan Glenn as Senior Independent Non-executive Director and Chairman-designate of the Company with immediate effect. Jonathan is an experienced board director and chairman, with an excellent track record in the medical device sector. He is currently Non-executive Chairman of Tissue Regenix plc, and was formerly Group CEO of Consort Medical Plc from 2007 to 2020, where he oversaw the £230 million acquisition of a European contract development and manufacturing organisation. Jonathan led the business as CEO until its acquisition for £505m in 2020. Jonathan is a member of the Institute of Chartered Accountants in England and Wales. He joins the board in anticipation of the upcoming retirement of Professor Mike McMahon, the founder of the Company, who retires from the board at the Annual General Meeting of the Company expected to take place on 27 June 2023. Following an orderly handover process, Jonathan will succeed Nigel Rogers as Chairman upon announcement of the interim results expected in September 2023. Nigel has indicated his intention to remain on the board until an additional independent non-executive director has been appointed. Jonathan Martin Glenn (aged54) is currently, or has during the past five years, been a director of the following companies: Current directorships or partnerships: Tissue Regenix Group plc; Tissue Regenix Holdings Limited; TRX Cardiac Limited; TRX Orthopaedics Limited; TRX Vascular Limited; TRX Wound Care Limited; Tissue Regenix Limited; Tissue Regenix Holdings Inc; Tissue Regenix Wound Care Inc; and TRX Orthopedics Inc. Previous directorships or partnerships: AESICA BC Limited; AESICA Formulation Development Limited; AESICA Holdco Limited; AESICA M1 Limited; AESICA M2 Limited; AESICA Queensborough Limited; AESICA Trustee Company Limited; Bespak Europe Limited; Bespak Finance Limited; Bespak Holdings Limited; Binx Health Limited; Consort Medical Finance 2010 Limited; Consort Medical Finance Limited; Consort Medical Limited; Consort Medical plc; Integrated Aluminium Components Limited; Medical House (ASI) Limited; Medical House Products Limited; Pharmaron Manufacturing Services (UK) Ltd; The Medical House Group Limited; and The Medical House Limited. Reported Earnings • Mar 30
Full year 2022 earnings released: EPS: UK£0 (vs UK£0 in FY 2021) Full year 2022 results: EPS: UK£0 (in line with FY 2021). Revenue: UK£11.3m (up 24% from FY 2021). Net income: UK£264.0k (up UK£720.0k from FY 2021). Profit margin: 2.3% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Jan 23
Surgical Innovations Group plc Provides Revenue Guidance for the Year Ended 31 December 2022 Surgical Innovations Group plc provided revenue guidance for the year ended 31 December 2022. For the year, the company revenues are expected to be approximately £11.3 million, an increase of more than 20% compared with the prior year (2021: £9.1 million) and 6% ahead of the pre-pandemic reference year (2019: £10.7 million). Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Paul Hardy was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 22
First half 2022 earnings released: EPS: UK£0 (vs UK£0 in 1H 2021) First half 2022 results: EPS: UK£0 (in line with 1H 2021). Revenue: UK£5.41m (up 28% from 1H 2021). Net loss: UK£14.0k (loss narrowed 85% from 1H 2021). Revenue is forecast to grow 6.0% p.a. on average during the next 2 years, compared to a 7.2% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Sep 02
Surgical Innovations Group plc to Report First Half, 2022 Results on Sep 21, 2022 Surgical Innovations Group plc announced that they will report first half, 2022 results on Sep 21, 2022 Announcement • Jul 30
Surgical Innovations Group plc Ordinary Shares to Be Deleted from OTC Equity Surgical Innovations Group plc Ordinary Shares United Kingdom(GB) will be deleted from OTC Equity effective from July 29, 2022, due to Inactive Security. Announcement • Jun 28
Surgical Innovations Group plc Provides Revenue Guidance for the Six Months to 30 June 2022 Surgical Innovations Group plc provided Revenue guidance for the six months to 30 June 2022. Revenues are showing significant growth and for the six months to 30 June 2022 are expected to be in excess of 22% above the comparable period last year. Announcement • May 25
Surgical Innovations Group plc, Annual General Meeting, Jun 27, 2022 Surgical Innovations Group plc, Annual General Meeting, Jun 27, 2022, at 09:00 Coordinated Universal Time. Location: Clayton Wood House, 6 Clayton Wood Bank, Leeds, LS16 6QZ Leeds United Kingdom Price Target Changed • Apr 27
Price target decreased to UK£0.033 Down from UK£0.042, the current price target is provided by 1 analyst. New target price is 47% above last closing price of UK£0.022. Stock is down 34% over the past year. The company posted a net loss per share of UK£0.00049 last year. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Paul Hardy was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jan 18
Surgical Innovations Group plc Provides Revenue Guidance for the Full Year 2021 Surgical Innovations Group plc announced that sales for the second half of the year were approximately 16% higher than the first half, resulting in revenue for the full year 2021 expected to be approximately £9.1 million. Reported Earnings • Apr 13
Full year 2020 earnings released: UK£0.004 loss per share (vs UK£0.003 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: UK£6.33m (down 41% from FY 2019). Net loss: UK£3.28m (loss widened 25% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 27
Full year 2020 earnings released: UK£0.004 loss per share (vs UK£0.003 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: UK£6.33m (down 41% from FY 2019). Net loss: UK£3.28m (loss widened 25% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance. Announcement • Mar 09
Surgical Innovations Group plc to Report Fiscal Year 2020 Results on Mar 25, 2021 Surgical Innovations Group plc announced that they will report fiscal year 2020 results on Mar 25, 2021 Announcement • Feb 16
Surgical Innovations Group plc Announces New USA Distribution Agreement with Microline Surgical Inc Surgical Innovations Group plc announced a new USA distribution agreement with Microline Surgical Inc. for the company's range of YelloPort+Plus and YelloPort Elite Access Devices. The 5-year agreement brings a significant opportunity to SI for growth in the US Trocar market. Microline's sales & marketing structure is ideally placed to leverage their experience with Resposable surgical instruments to effectively drive US sales of YelloPort+Plus and YelloPort Elite Access Devices. Based near Boston, MA, U.S.A. Microline designs, manufactures and distributes high quality instruments aimed at the MIS market. Its portfolio of products is complementary to those offered by SI with a focus on the resposable ethos of cost and sustainability. SI has a long established relationship with Microline, where it has an exclusive GB distribution agreement for Microline instruments that are complementary to the SI branded range. Announcement • Jan 08
Surgical Innovations Group plc Announces Adam Power Will Retire as Group Development Director, with Effect from 31 December 2021 Surgical Innovations Group plc announced that Adam Power, Group Development Director, has provided twelve months' notice to the Board that he wishes to retire from his executive role as Group Development Director, with effect from 31 December 2021. The current intention is that he will subsequently continue to serve as a Non-executive Director for a further twelve months until 31 December 2022. Announcement • Dec 18
Surgical Innovations Group plc Announces Distribution Agreement with Adler Instrument Company Inc Surgical Innovations Group plc announced a new nationwide distribution agreement with existing US distributor, Adler Instrument Company Inc. ("Adler"), for the company's full range of handheld surgical instruments, consolidating its product distribution in the United States. The agreement brings a significant increase in the number of surgical territory managers promoting SI-branded products across the US. This five-year exclusive contract worth approximately $12m over its duration is effective from February 1, 2021, and will ensure the future success of the LogiCut and EcoCut scissor brands as well as providing a route into the US for the anticipated growth of new Logi-branded products. Florida-based Adler, is a highly experienced distribution company with access to nationwide coverage and are already working on converting a number of significant accounts from competing products to using the SI range of instruments. Announcement • Nov 27
Surgical Innovations Group plc Announces its Collaboration with the Centre for Sustainable Healthcare Surgical Innovations Group plc announced its collaboration with the Centre for Sustainable Healthcare to support wider efforts in the UK and globally to reduce the environmental impact of plastic waste in surgery. This new collaboration with CSH will enable the validation of the Company's environmental messaging and demonstrate the quantifiable cost and environmental savings from a 'greener' operating room. This data will then help develop information and training for NHS hospitals and staff as they seek to fulfil obligations on sustainability in the NHS, and follows the publication in October 2020 of the NHS 'Net Zero' objective, described more fully in the link below. Surgical Innovations' range of 'Resposable™' surgical instruments is designed to provide class leading quality and functionality, whilst reducing plastic waste by approximately 70% compared to that generated from commonly used competing products. In addition, CSH's global network will help direct the Company's efforts to promote the Green credentials of its "Resposable™ product portfolio to existing and new international partners. Announcement • Aug 21
Surgical Innovations Group plc to Report First Half, 2020 Results on Sep 08, 2020 Surgical Innovations Group plc announced that they will report first half, 2020 results on Sep 08, 2020 
